Generic Zanaflex ( Tizanidine )

Buy Generic Zanaflex (Tizanidine) without prescription in Canada

Zanaflex (Tizanidine 2 mg, 4 mg): Comprehensive Patient Information for Canada

Basic Product Information

Mechanism of Action

In simple terms: Zanaflex is a muscle relaxant that works in the brain and spinal cord to reduce muscle stiffness and spasms. It works by mimicking the effects of a natural chemical called noradrenaline, which helps calm overactive nerve signals that cause muscles to tighten. By doing this, it temporarily relaxes tense, rigid muscles, making it easier to move and reducing pain associated with spasticity.

For specialists: Tizanidine is a central alpha-2-adrenergic receptor agonist. It presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. The effects of tizanidine are greatest on polysynaptic pathways. The overall effect of these actions is thought to reduce facilitation of spinal motor neurons. In animal models, tizanidine has no direct effect on skeletal muscle fibers or the neuromuscular junction, and no major effect on monosynaptic spinal reflexes. The imidazoline chemical structure of tizanidine is related to that of the antihypertensive drug clonidine and other alpha-2-adrenergic agonists. Pharmacological studies in animals show similarities between the two compounds, but tizanidine was found to have one-tenth to one-fiftieth of the potency of clonidine in lowering blood pressure.

Pharmacokinetics

• Absorption: Following oral administration, tizanidine is essentially completely absorbed. The absolute oral bioavailability of tizanidine is approximately 40% (CV = 24%), due to extensive first-pass hepatic metabolism. Tizanidine capsules and tablets are bioequivalent to each other under fasting conditions, but not under fed conditions. A single dose of either two 4 mg tablets or two 4 mg capsules was administered under fed and fasting conditions in an open-label, four-period, randomized crossover study in 96 volunteers. Pharmacokinetics under fed conditions were different than under fasting conditions and vary by dosage form.
• Metabolism: Approximately 95% of an administered dose is metabolized. The primary cytochrome P450 isoenzyme involved in tizanidine metabolism is CYP1A2. Tizanidine metabolites are not known to be active; their half-lives range from 20 to 40 hours.
• Elimination: Following single and multiple oral dosing of 14C-tizanidine, an average of 60% and 20% of total radioactivity was recovered in the urine and feces, respectively. Tizanidine has a half-life of approximately 2.5 hours (CV = 33%).
• Distribution: Tizanidine is extensively distributed throughout the body with a mean steady state volume of distribution of 2.4 L/kg (CV = 21%) following intravenous administration in healthy adult volunteers. Tizanidine is approximately 30% bound to plasma proteins.
• Onset of Action: Following oral administration, symptomatic relief of muscle spasticity typically begins within 1 to 2 hours. The medication is usually taken every 6 to 8 hours as directed by a doctor.
• Duration of Action: The therapeutic effect typically lasts for approximately 3 to 6 hours, supporting dosing three to four times daily.

Uses in Daily Life and Best Practice Advice

Tizanidine is prescribed in Canada for the treatment of spasticity. Your physician will determine the appropriate use and dose based on your specific medical situation.

• Typical Uses: Treatment of spasticity associated with multiple sclerosis or other conditions resulting from spinal cord lesions. It is also used for muscle spasm associated with acute, painful musculoskeletal conditions and chronic low-back pain.
• Administration: Take the tablet orally as directed by your doctor, usually every 6 to 8 hours. The dose may be increased gradually by 2 mg to 4 mg per dose, with 1 to 4 days between increases, until a satisfactory reduction of muscle tone is achieved. Swallow the tablet whole with a glass of water.
• Monitoring: Monitoring of aminotransferase levels is recommended at baseline and 1 month after maximum dose is achieved. Your physician should also monitor for muscle weakness, urinary retention, cognitive changes, sedation, and orthostatic hypotension.
• Do Not Stop Without Medical Advice: Do not stop taking this medication abruptly without consulting your physician. Gradual dose reduction is recommended when discontinuing treatment.

Morning vs. Evening Dosing

Tizanidine is typically taken every 6 to 8 hours. There is no specific clinical recommendation for morning versus evening dosing. However, because drowsiness is a common side effect, taking the dose in the evening may help minimize daytime sedation. Always follow the schedule recommended by your physician.

• Divided Dosing: The daily dose is usually divided into three or four doses taken throughout the day.
• Consistency: Take tizanidine at the same times each day to ensure consistent effects.
• Missed Dose: If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time.
• Professional Guidance: Your healthcare provider may adjust the frequency and timing based on your response to treatment.

Administration With or Without Food

Tizanidine can be taken with or without food. However, the pharmacokinetics of tizanidine tablets and capsules differ when administered with food. Food significantly affects the absorption of tizanidine, and the tablets and capsules are not interchangeable in the fed state. To ensure consistent absorption, it is generally recommended to take tizanidine consistently with regard to food.

• Take the tablet with a full glass of water.
• Tizanidine can be taken with or without food, but be consistent.
• Do not switch between different formulations or brands without consulting your physician or pharmacist, as they may not be interchangeable when taken with food.
• Avoid drinking alcohol while taking tizanidine, as it can increase drowsiness and the risk of serious side effects.

Interaction Warnings

Indications for Tizanidine

"Off-label" means use outside the official approved indication, usually based on current medical guidelines and scientific evidence.

Dosing According to Clinical Indication

Doses should always be adjusted according to the advice of your physician and depending on your health condition. The dose should be titrated slowly to minimize side effects. Do not stop abruptly; gradual dose reduction is recommended.

Side Effects and Safety Profile

Guidelines for Correct Use

• Take tizanidine exactly as prescribed by your physician. Do not change your dose without medical advice.
• Take the tablet with a full glass of water, with or without food, but be consistent.
• Do not switch between different formulations or brands without consulting your physician or pharmacist.
• Do not stop taking tizanidine abruptly. Your physician will provide a gradual dose reduction plan.
• Avoid drinking alcohol while taking tizanidine, as it can increase drowsiness and the risk of serious side effects.
• Do not drive or operate machinery until you know how tizanidine affects you.
• Keep all medical appointments for monitoring of liver function and blood pressure.
• Inform every healthcare provider (including dentists, surgeons, and pharmacists) that you are taking tizanidine.
• If you are pregnant, planning to become pregnant, or breastfeeding, consult your physician before use.
• If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose. Do not double the dose.
• Store at room temperature in a dry place. Keep out of reach of children.

Alternative Treatment Options

• Baclofen (Lioresal): A muscle relaxant that acts on the spinal cord. Available in 10 mg and 20 mg tablets. Often used for muscle spasticity associated with neurological conditions. In Ontario, tizanidine is covered as a Limited Use benefit specifically for patients who have failed therapy with or are intolerant to baclofen.
• Cyclobenzaprine (Flexeril): A muscle relaxant used for acute musculoskeletal conditions. Available in 10 mg tablets. Structurally related to tricyclic antidepressants. Structurally related to tricyclic antidepressants and has significant anticholinergic effects.
• Methocarbamol (Robaxin): A muscle relaxant available in 500 mg and 750 mg tablets. Used for acute musculoskeletal pain. May cause drowsiness and dizziness.
• Dantrolene (Dantrium): A peripherally acting muscle relaxant that works directly on muscle tissue. Used for spasticity of various origins. Requires monitoring of liver function and carries a black-box warning for potentially fatal hepatotoxicity.
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) (e.g., ibuprofen, naproxen): Used for pain and inflammation. May be used alone or in combination with muscle relaxants.
• Acetaminophen: An analgesic for pain relief. May be used alone or in combination with other therapies.

Comparison: Tizanidine is distinguished from other muscle relaxants by its central alpha-2-adrenergic agonist mechanism and its well-studied efficacy for low-back pain. It is associated with lower rates of injury, delirium, encephalopathy, falls, and opioid-overdose compared with baclofen in older adults with musculoskeletal pain. Tizanidine and chlorzoxazone can cause reversible, generally non-serious hepatotoxicity, whereas dantrolene carries a black-box warning for potentially fatal hepatotoxicity. In Ontario, tizanidine is a Limited Use benefit for multiple sclerosis-related spasticity after failure or intolerance to baclofen. Your physician will determine the best option for your specific condition.

Legal Status, Registration, and Coverage in Canada

• Registration: Tizanidine hydrochloride is authorized for sale in Canada by Health Canada as a prescription drug. Health Canada issued a Notice of Compliance for Zanaflex on June 29, 1999. APO-TIZANIDINE is approved (DIN 02259885, status date 2023-10-25). Other generic formulations include Mylan-Tizanidine (DIN 02272059) and Mint-Tizanidine (DIN 02536765).
• Prescription Status: Prescription only in Canada.
• Coverage: Coverage varies by province and territory. In Ontario, Apo-Tizanidine 4 mg is listed as an Off-Formulary Interchangeable product with a drug benefit price of $0.8758 per tablet. Tizanidine is a Limited Use benefit requiring prior approval for the treatment of spasticity in patients with multiple sclerosis who have failed therapy with or are intolerant to baclofen. In Quebec, tizanidine is covered under the RAMQ formulary at $0.3686 per tablet (Mint-Tizanidine 4 mg and Tizanidine Apotex 4 mg). In Newfoundland and Labrador, Apo-Tizanidine and Mint-Tizanidine are covered under the provincial drug plan. Generic formulations are generally more affordable than the brand-name product.
• Pharmacovigilance: Adverse reactions should be reported to Health Canada's MedEffect Canada program at 1-866-234-2345.

Recent Research and Clinical Guidelines (2022–2026)

• The 2026 guideline recommendations for muscle-relaxant therapy in chronic low-back pain state that tizanidine has been well studied for low-back pain, whereas there is little evidence supporting the efficacy of baclofen or dantrolene for this indication. The guideline recommends initiating tizanidine at 2 mg up to three times daily, with monitoring for muscle weakness, urinary retention, cognitive changes, sedation, and orthostatic hypotension.
• The 2026 guideline for muscle relaxant use in elderly patients with acute muscle spasm identifies tizanidine (starting at 2 mg up to three times daily, lowest effective dose) as the preferred muscle relaxant for acute spasm in older adults. When prescribing tizanidine, monitor for muscle weakness and orthostatic hypotension, which raises fall risk.
• The 2026 ACP/APS guidelines note that tizanidine is associated with lower rates of injury, delirium, encephalopathy, falls, and opioid-overdose compared with baclofen in older adults with musculoskeletal pain. Both tizanidine and chlorzoxazone can cause reversible, generally non-serious hepatotoxicity, whereas dantrolene carries a black-box warning for potentially fatal hepatotoxicity.
• The 2026 Journal of the American Geriatrics Society recommends periodic monitoring of liver-function tests while patients are receiving tizanidine or baclofen.
• Updated prescribing information from February and March 2026 confirms that monitoring of aminotransferase levels is recommended at baseline and 1 month after maximum dose is achieved.
• Research continues to explore the role of tizanidine in various clinical settings, including its use as a muscle relaxant in patients with cirrhosis (Child A and B: safe; Child C: use with caution, initiate at low dose and titrate slowly).

Availability and Supply in Canada

Prices and availability may vary by province, territory, and pharmacy. Generic tizanidine 2 mg and 4 mg tablets are widely available in Canada and are generally more affordable than the brand-name product. In Ontario, Apo-Tizanidine 4 mg is listed as an Off-Formulary Interchangeable product at $0.8758 per tablet. In Quebec, tizanidine is covered at $0.3686 per tablet. Check with your local pharmacy for current pricing and availability.

Frequently Asked Questions (FAQ)

1. What is Zanaflex used for?
   Zanaflex (tizanidine) is used to treat spasticity, a condition in which muscles become tight and stiff. It is particularly used for spasticity associated with multiple sclerosis or other conditions resulting from spinal cord lesions. It is also used for muscle spasm associated with acute, painful musculoskeletal conditions and chronic low-back pain.
2. How long does tizanidine take to work?
   Tizanidine begins to take effect within 1 to 2 hours after oral administration. The therapeutic effect typically lasts for approximately 3 to 6 hours, which is why it is usually taken every 6 to 8 hours.
3. What is the correct dose of tizanidine?
   The usual starting dose is 2 mg up to three times daily. The initial daily dose should not exceed 6 mg in 3 divided doses. The dose may be increased in steps by 2 to 4 mg at intervals of half or full week. The optimal daily dose for a therapeutic response is generally between 12 and 24 mg. The total daily dose should not exceed 36 mg.
4. Can I take tizanidine with food?
   Yes, tizanidine can be taken with or without food, but you should be consistent. The pharmacokinetics of tizanidine tablets and capsules differ when administered with food, and they are not interchangeable in the fed state.
5. What should I do if I miss a dose?
   If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time.
6. Can I drink alcohol while taking tizanidine?
   No. Alcohol should not be consumed while taking tizanidine because it can increase drowsiness and the risk of serious side effects.
7. What are the serious side effects of tizanidine?
   Serious side effects include liver injury, severe hypotension, and sedation. Monitoring of aminotransferase levels is recommended at baseline and 1 month after maximum dose is achieved. Seek immediate medical attention if you experience signs of liver problems, fainting, or severe drowsiness.
8. Is tizanidine safe during pregnancy?
   Tizanidine should be used during pregnancy only if clearly needed. There are no adequate data on the developmental risk associated with use in pregnant women. Consult your physician if you are pregnant or planning to become pregnant.
9. Is tizanidine safe during breastfeeding?
   It is not known if tizanidine passes into breast milk. Consult your physician before use if breastfeeding.
10. Are there generic versions of tizanidine available in Canada?
    Yes. Generic tizanidine is widely available in Canada in 2 mg and 4 mg strengths from multiple manufacturers, including Apotex, Mylan, Mint Pharmaceuticals, and Paladin Labs. Generic versions are generally more affordable than the brand-name product.
11. Is tizanidine covered by Canadian health insurance?
    Coverage varies by province and territory. In Ontario, tizanidine is a Limited Use benefit requiring prior approval for multiple sclerosis-related spasticity after failure or intolerance to baclofen. In Quebec, tizanidine is covered under the RAMQ formulary. Check with your provincial drug plan and private insurance provider for coverage details.